These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34085581)

  • 21. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.
    Pearson DA; Santos CW; Aman MG; Arnold LE; Casat CD; Mansour R; Lane DM; Loveland KA; Bukstein OG; Jerger SW; Factor P; Vanwoerden S; Perez E; Cleveland LA
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):337-51. PubMed ID: 23782128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
    Liu T; Gobburu JVS; Po MD; McLean A; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):181-191. PubMed ID: 30810347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Belchenko D; Lempa B
    Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
    Matthijssen AM; Dietrich A; Bierens M; Kleine Deters R; van de Loo-Neus GHH; van den Hoofdakker BJ; Buitelaar JK; Hoekstra PJ
    Am J Psychiatry; 2019 Sep; 176(9):754-762. PubMed ID: 31109200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
    Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
    Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.
    Döpfner M; Görtz-Dorten A; Breuer D; Rothenberger A
    Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S243-55. PubMed ID: 21901417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
    Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
    Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.